Ocular Therapeutix – Piper Sandler Fireside Chat - OCULAR THERAPEUTIX INC

Financial Performance:

• Company holds nearly $600 million in cash and cash equivalents, providing a runway extending to 2028.
• Funding covers commercial preparation, NDA filing, and potential launch activities without immediate capital raising needs.
• No specific revenue, earnings, or margin figures provided as the company remains pre-commercialization.

Guidance and Future Outlook:

• NDA filing for Xpaxity (XPAX) is on track for the fourth quarter of the current year following a successful pre-NDA meeting.
• Anticipated approval in 2027, with a commercial launch targeted for the second half of 2028.
• The Helios trial for diabetic retinopathy is ongoing globally; enrollment is proceeding with careful patient selection, though specific completion dates are not yet guided.
• Management expects a superiority label with dosing flexibility (6 to 12 months) and explicit approval for repeat dosing, supported by sufficient safety data from redosed patients in SOL-1.

Business Segments and Product Lines:

• Xpaxity (XPAX): A TKI-based ophthalmic drug designed as a maintenance therapy for wet AMD, demonstrating superiority over aflibercept (Eylea) in the SOL-1 trial with a robust p-value (<0.0006).
• SOL-1 Trial: Completed with robust data showing durability (approx. 60% of patients sustained 12 months without rescue) and disease control (OCT stability within 30 microns at month 9).
• SOLAR Trial: Preserved as a non-inferiority study for potential international regulatory approvals (OUS), not currently required for FDA submission but maintaining integrity as a safety net.
• Diabetic Retinopathy: Pipeline program (Helios study) targets a market 3.5x larger than wet AMD, aiming for a single-injection annual therapy to prevent blinding complications.
• Commercial Preparation: Scaling up manufacturing and personnel, with David Robinson leading the launch strategy.

Market and Competitive Landscape:

• Competitive Position: XPAX is positioned as the only maintenance therapy in the field; management states it faces no direct competition currently as iPoint (a prior maintenance competitor) has failed.
• Kodiak (Tarkozyma): Classified as a "bolus" injection (PRN), not a direct competitor to XPAX's maintenance model; regulatory path for PRN drugs is viewed as uncertain by management.
• Historical Context: Management counters negative perceptions of TKIs by attributing past failures to poor patient selection and route of administration (oral/IV) rather than the drug class itself.
• Gene Therapy: Viewed as a high-bar, long-term alternative rather than immediate competition, given the need for "perfection" over decades and the availability of effective intravitreal treatments.
• Patient Selection: SOL-1 utilized an unprecedented, rigorous patient selection process (6-month ramp, strict OCT stability criteria) to eliminate "anti-VEGF addicts," a factor management claims contributed significantly to the study's success compared to failed iPoint studies.

Risks and Challenges:

• Regulatory Risk: Management acknowledges the hypothetical (though unlikely) risk of the FDA requesting SOLAR data, which could trigger a major amendment and reset review timelines.
• Clinical Trial Risks: Diabetic retinopathy market faces challenges with patient adherence due to asymptomatic nature; however, the "once-yearly" regimen is designed to mitigate this compared to monthly injections.
• Data Disclosure: Need to balance shareholder information requests with FDA collaboration requirements; no premature data release will occur during the NDA review to maintain trial integrity.
• Future Competition: While no current maintenance competitors exist, the market dynamics remain fluid with various bolus therapies (Avastin, Vabysmo, Kodiak) acting as substitutes.

Management Commentary and Tone:

• Tone: Highly confident, assertive, and defensive regarding the drug's potential and the trial design. Management emphasizes execution and adherence to FDA guidance.
• FDA Relationship: Strongly positive; management cites seamless collaboration with the FDA, including multiple Special Protocol Assessments (SPAs) for both wet AMD and diabetic retinopathy.
• Leadership Stability: Expressed zero concern regarding the upcoming retirement of FDA Ophthalmology Director Dr. Bill Boyd and the transition to Dr. Rhea Loy, citing her long tenure and "lockstep" alignment with previous leadership.
• Executive Stance: CEO Praveen Dougal emphasizes a clinician's perspective, arguing that past TKI failures were due to study design errors, not the molecule, and highlighting the drug's superior safety profile via patient-level data release.

Analyst Questions and Answers:

• Q: FDA Leadership Changes: A: No impact expected; Dr. Loy has been involved in all meetings and signed off on all approvals.
• Q: Competitor Data (iPoint/Kodiak) Impact: A: FDA has not seen raw data from failed iPoint or positive Kodiak studies; decisions are based on raw data submission, not press releases. Class effects do not apply.
• Q: SOLAR Readout Timing: A: Delayed readout is intentional to avoid "card turns" during the review process that would force the FDA to re-examine data, potentially delaying approval.
• Q: Pricing and Label: A: Expect a premium pricing strategy due to the unique "superiority" label and lack of direct competition. Label likely to include 6-12 month dosing flexibility.
• Q: First-line vs. Maintenance: A: Data currently supports a "maintenance" label; first-line use is being explored but not yet proven.
• Q: Gene Therapy Competition: A: High barrier to entry for gene therapy; XPAX offers a safer, reversible alternative with proven durability.
• Q: Diabetic Retinopathy Market Size: A: Market is "ginormous" and undervalued by the market; management plans to highlight this opportunity post-NDA filing.
• Q: OSN Meeting Attendance: A: Legal issues with iPoint have resolved; Ocular Therapeutics is expected to present at the upcoming OSN meeting.

Other Key Points:

• Safety Profile: XPAX has released patient-level safety data to demonstrate a superior safety profile compared to competitors.
• Study Design: SOL-1 used a strict definition of "dryness" (<10 nanoliters fluid) which management claims is the strictest in the industry.
• Regulatory Strategy: The company is pursuing a single-trial submission for the US, relying on the SOL-1 data, while SOLAR remains a parallel asset for international use.
• Market Education: Future marketing will focus on the convenience of annual injections for diabetic retinopathy, positioning it as a preventative measure similar to dental cleanings.
• Insider Confidence: CEO explicitly states he is a shareholder and cares about the stock performance, countering the narrative that he is indifferent to valuation.